Canada Markets open in 9 hrs 15 mins

Can-Fite BioPharma Ltd. (CANF)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.9100+0.0100 (+1.11%)
At close: 03:53PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) N/A
Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 1.66
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 32.6200
52 Week Low 30.7800
50-Day Moving Average 31.0126
200-Day Moving Average 31.3044

Share Statistics

Avg Vol (3 month) 3180.3k
Avg Vol (10 day) 372.67k
Shares Outstanding 520.07M
Implied Shares Outstanding 6N/A
Float 827.18M
% Held by Insiders 10.00%
% Held by Institutions 11.43%
Shares Short (Apr 28, 2022) 4479.72k
Short Ratio (Apr 28, 2022) 42.63
Short % of Float (Apr 28, 2022) 4N/A
Short % of Shares Outstanding (Apr 28, 2022) 41.76%
Shares Short (prior month Mar 30, 2022) 4770.09k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3May 09, 2019
Ex-Dividend Date 4N/A
Last Split Factor 21:15
Last Split Date 3May 09, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Dec 30, 2021


Profit Margin 0.00%
Operating Margin (ttm)-1,505.51%

Management Effectiveness

Return on Assets (ttm)-53.91%
Return on Equity (ttm)-123.34%

Income Statement

Revenue (ttm)853k
Revenue Per Share (ttm)0.06
Quarterly Revenue Growth (yoy)36.00%
Gross Profit (ttm)853k
EBITDA -12.83M
Net Income Avi to Common (ttm)-15.21M
Diluted EPS (ttm)-0.6900
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)19.14M
Total Cash Per Share (mrq)0.7
Total Debt (mrq)124k
Total Debt/Equity (mrq)0.86
Current Ratio (mrq)7.35
Book Value Per Share (mrq)0.48

Cash Flow Statement

Operating Cash Flow (ttm)-9.86M
Levered Free Cash Flow (ttm)-5.98M